Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

>Adverse Reactions

In controlled Crohn's clinical trials, the most common adverse events that occurred in greater than or equal to 5% of certolizumab Pegol patients (n=620) and more frequently than with placebo (n=614) were upper respiratory infection (20% certolizumab pegol, 13% placebo), urinary tract infection (7% certolizumab pegol, 6% placebo), and arthralgia (6% certolizumab pegol, 4% placebo).  The proportion of patients who discontinued treatment due to adverse reactions in the controlled clinical studies was 8% for certolizumab pegol and 7% for placebo.

In controlled RA clinical trials, the most common adverse events that occurred in greater than or equal to 3% of patients taking certolizumab pegol 200mg every other week with concomitant methotrexate (n=640) and more frequently than with placebo with concomitant methotrexate (n=324) were upper respiratory tract infection (6% certolizumab pegol, 2% placebo), headache (5% certolizumab pegol, 4% placebo), hypertension (5% certolizumab pegol, 2% placebo), nasopharyngitis (5% certolizumab pegol, 1% placebo), back pain (4% certolizumab pegol, 1% placebo), pyrexia (3% certolizumab pegol, 2% placebo), pharyngitis (3% certolizumab pegol, 1% placebo), rash (3% certolizumab pegol, 1% placebo), acute bronchitis (3% certolizumab pegol,1% placebo), fatigue (3% certolizumab pegol, 1% placebo).  Hypertensive adverse reactions were observed more frequently in patients receiving certolizumab pegol than in controls.  These adverse reactions occurred more frequently among patients with a baseline history of hypertension and among patients receiving concomitant corticosteroids and nonsteroidal anti-inflammatory drugs.  Patients receiving certolizumab pegol 400mg as monotherapy every 4 weeks in RA controlled clinical trials had similar adverse reactions to those patients receiving certolizumab pegol 200mg every other week.  The proportion of patients who discontinued treat
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... SAN ANTONIO , May 6, 2015   GenSpera, ... "Injectable Cancer Compositions" has entered the national phase application process ... , Eurasia, Japan , China ... the United States . When awarded, the resulting patent ... property around its entire platform technology, including its lead drug ...
(Date:5/6/2015)... , May 6, 2015 ... What does the future hold for the ... brand new report shows you potential revenues to 2025, ... Our new 189 page report provides 115 tables, charts, ... most lucrative areas in the industry and the future ...
(Date:5/6/2015)... , May 6, 2015  TriStar Wellness ... company that targets opportunities in the advanced wound ... Portland, Oregon based wholly owned independent ... awarded funding from the National Institutes of Health ... dressing that is able to be delivered by ...
Breaking Medicine Technology:GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations 2Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 2Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 3Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 4Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 5Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 6Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 2Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 3Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 4Collaboration Between HemCon and OHSU is Awarded Additional NIH Grant with Total Value of $1.1M for the Development of a Transurethral Hemostatic Device 5
(Date:5/6/2015)... 2015 As Hilo Medical Center ... Adoption Model, the hospital looked for new applications ... automate processes. The leadership team realized that while ... workflows, patient registration still required patients to apply ... HIMSS Stage 7 attestation fast approaching, Hilo looked ...
(Date:5/6/2015)... FL- May 05, 2014 (PRWEB) May 06, 2015 ... Grant Lock accepted, on behalf of MEBC, an ... organizations from JDA Software during FOCUS 2015, JDA’s ... attendees across the manufacturing, retail and wholesale distribution ... ensuring that their clients are receiving services that ...
(Date:5/6/2015)... 2015 The Beryl Institute announces the ... Patient Experience Journal (PXJ), an international, open access, peer-reviewed ... and improving patient experience. The second volume of PXJ ... globally, helps align the voices engaged and provides the ... in association with The Beryl Institute, Volume 2, Issue ...
(Date:5/6/2015)... Los Angeles (PRWEB) May 06, 2015 ... WaterAid, the #1 ranked international water, sanitation and hygiene ... work for communities across the world and it brings ... Lindsey Carnett, CEO of Marketing Maven. “The ongoing relationship ... the opportunities available for people to learn about and ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Wolters ... healthcare professionals and students, announced today that in a ... confirmed that use of the clinical decision support resource ... the end of 2014, UpToDate users in more than ... topics per month, on average. In Germany alone, 95% ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3
... Tahitian ... degrade rapidly, the iridoids in Tahitian Noni Bioactive Beverages are found to be extremely ... ... that, unlike the flavonoids and carotenoids in major superfruit juices that degrade rapidly, the ...
... The Net Impact ... to Promote National Mental Health Awareness Campaign , ... St. Louis, MO (PRWEB) March 25, 2010 -- The Karla Smith Foundation, ... a loved one suffering from mental illness and those who have lost a loved one ...
... found that even before infants begin to speak, words play ... influence performance in a cognitive task in a way that ... musical tones. The research by Alissa Ferry, ... the Weinberg College of Arts and Sciences, will appear in ...
... ... three drive autoloader with a compact body suitable for any office space. , ... (Vocus) March 25, 2010 -- Vinpower Digital announced today the ... autoloader duplication system. This unit offers many of the options and benefits expected ...
... ... (ARI) announced it purchased key technology assets from Regenerative Medicine Assets Limited (formerly Intercytex ... ... -- Aderans Research Institute Inc. (ARI) announced it purchased key technology assets from Regenerative ...
... "This ... customers," said President & CEO Sarav Periasamy, PERI Software Solutions Inc. , ... Tampa, FL/Newark, NJ (PRWEB) March ... their business -- from customer care to service delivery and infrastructure management,” said ...
Cached Medicine News:Health News:Flavonoids and Carotenoids are Not as Stable After Processing as Iridoids: Most Superfruit Juices Do Not Contain Iridoids 2Health News:The Net Impact Creates Website for St. Louis Event to Combat the Stigma of Mental Illness 2Health News:The Net Impact Creates Website for St. Louis Event to Combat the Stigma of Mental Illness 3Health News:The Net Impact Creates Website for St. Louis Event to Combat the Stigma of Mental Illness 4Health News:Talk to your babies 2Health News:Vinpower Digital Introduces the 3 Drive CUBE Autoloader Series 2Health News:Aderans Research Acquires Intercytex Assets 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 2Health News:PERI Software Solutions CEO Sarav Periasamy to Attend DistribuTECH Conference and Exhibition in Tampa, FL 3
... Indirect Ophthalmoscope Power Source provides power to ... ophthalmic instruments. The versatile wall/desk power source ... or on the side of a desk ... portable power pack provides power no matter ...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Welch Allyn quality in a convenient pocket size. The PocketScope fits into your pocket! Easy to use, lightweight, and perfect for general and specialist use. Take your PocketScope with you everywhere...
... ALE-3600 and ALE-3600PC Patternless ... fit lenses to frames, ... the convenience of complete ... edgers are particularly suited ...
Medicine Products: